270 related articles for article (PubMed ID: 27193582)
1. Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride.
Jalily PH; Eldstrom J; Miller SC; Kwan DC; Tai SS; Chou D; Niikura M; Tietjen I; Fedida D
Mol Pharmacol; 2016 Aug; 90(2):80-95. PubMed ID: 27193582
[TBL] [Abstract][Full Text] [Related]
2. An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
Hu Y; Musharrafieh R; Ma C; Zhang J; Smee DF; DeGrado WF; Wang J
Antiviral Res; 2017 Apr; 140():45-54. PubMed ID: 28087313
[TBL] [Abstract][Full Text] [Related]
3. Virtual Screening Identifies Chebulagic Acid as an Inhibitor of the M2(S31N) Viral Ion Channel and Influenza A Virus.
Duncan MC; Onguéné PA; Kihara I; Nebangwa DN; Naidu ME; Williams DE; Balgi AD; Andrae-Marobela K; Roberge M; Andersen RJ; Niikura M; Ntie-Kang F; Tietjen I
Molecules; 2020 Jun; 25(12):. PubMed ID: 32599753
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Potent Antivirals against Amantadine-Resistant Influenza A Viruses by Targeting the M2-S31N Proton Channel.
Li F; Ma C; Hu Y; Wang Y; Wang J
ACS Infect Dis; 2016 Oct; 2(10):726-733. PubMed ID: 27657178
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.
Ma C; Zhang J; Wang J
Mol Pharmacol; 2016 Sep; 90(3):188-98. PubMed ID: 27385729
[TBL] [Abstract][Full Text] [Related]
6. The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers.
Musharrafieh R; Lagarias PI; Ma C; Tan GS; Kolocouris A; Wang J
Mol Pharmacol; 2019 Aug; 96(2):148-157. PubMed ID: 31175183
[TBL] [Abstract][Full Text] [Related]
7. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus.
Balannik V; Wang J; Ohigashi Y; Jing X; Magavern E; Lamb RA; Degrado WF; Pinto LH
Biochemistry; 2009 Dec; 48(50):11872-82. PubMed ID: 19905033
[TBL] [Abstract][Full Text] [Related]
8. Characterization of inhibition of M2 ion channel activity by BL-1743, an inhibitor of influenza A virus.
Tu Q; Pinto LH; Luo G; Shaughnessy MA; Mullaney D; Kurtz S; Krystal M; Lamb RA
J Virol; 1996 Jul; 70(7):4246-52. PubMed ID: 8676445
[TBL] [Abstract][Full Text] [Related]
9. Why bound amantadine fails to inhibit proton conductance according to simulations of the drug-resistant influenza A M2 (S31N).
Gleed ML; Busath DD
J Phys Chem B; 2015 Jan; 119(3):1225-31. PubMed ID: 25426702
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of pinanamine derivatives as anti-influenza A M2 ion channel inhibitors.
Zhao X; Jie Y; Rosenberg MR; Wan J; Zeng S; Cui W; Xiao Y; Li Z; Tu Z; Casarotto MG; Hu W
Antiviral Res; 2012 Nov; 96(2):91-9. PubMed ID: 22982118
[TBL] [Abstract][Full Text] [Related]
11. Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture.
Takeda M; Pekosz A; Shuck K; Pinto LH; Lamb RA
J Virol; 2002 Feb; 76(3):1391-9. PubMed ID: 11773413
[TBL] [Abstract][Full Text] [Related]
12. Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
Duque MD; Ma C; Torres E; Wang J; Naesens L; Juárez-Jiménez J; Camps P; Luque FJ; DeGrado WF; Lamb RA; Pinto LH; Vázquez S
J Med Chem; 2011 Apr; 54(8):2646-57. PubMed ID: 21466220
[TBL] [Abstract][Full Text] [Related]
13. Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.
Rey-Carrizo M; Barniol-Xicota M; Ma C; Frigolé-Vivas M; Torres E; Naesens L; Llabrés S; Juárez-Jiménez J; Luque FJ; DeGrado WF; Lamb RA; Pinto LH; Vázquez S
J Med Chem; 2014 Jul; 57(13):5738-47. PubMed ID: 24941437
[TBL] [Abstract][Full Text] [Related]
14. Novel spirothiazamenthane inhibitors of the influenza A M2 proton channel.
Arns S; Balgi AD; Shimizu Y; Pfeifer TA; Kumar N; Shidmoossavee FS; Sun S; Tai SS; Agafitei O; Jaquith JB; Bourque E; Niikura M; Roberge M
Eur J Med Chem; 2016 Sep; 120():64-73. PubMed ID: 27187859
[TBL] [Abstract][Full Text] [Related]
15. 3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
Rey-Carrizo M; Torres E; Ma C; Barniol-Xicota M; Wang J; Wu Y; Naesens L; DeGrado WF; Lamb RA; Pinto LH; Vázquez S
J Med Chem; 2013 Nov; 56(22):9265-74. PubMed ID: 24237039
[TBL] [Abstract][Full Text] [Related]
16. Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7.
Mandour YM; Breitinger U; Ma C; Wang J; Boeckler FM; Breitinger HG; Zlotos DP
Drug Des Devel Ther; 2018; 12():1019-1031. PubMed ID: 29750015
[TBL] [Abstract][Full Text] [Related]
17. How to overcome resistance of influenza A viruses against adamantane derivatives.
Scholtissek C; Quack G; Klenk HD; Webster RG
Antiviral Res; 1998 Feb; 37(2):83-95. PubMed ID: 9588841
[TBL] [Abstract][Full Text] [Related]
18. Viral M2 ion channel protein: a promising target for anti-influenza drug discovery.
Moorthy NS; Poongavanam V; Pratheepa V
Mini Rev Med Chem; 2014; 14(10):819-30. PubMed ID: 25342196
[TBL] [Abstract][Full Text] [Related]
19. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
[TBL] [Abstract][Full Text] [Related]
20. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus.
Wang J; Wu Y; Ma C; Fiorin G; Wang J; Pinto LH; Lamb RA; Klein ML; Degrado WF
Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1315-20. PubMed ID: 23302696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
